Omeros (OMER) EBT Margin (2010 - 2026)

Omeros (OMER) reported EBT Margin of 518.61% for Q1 2026, up 225.65% sequentially from 412.74% in Q2 2022.

Omeros (OMER) EBT Margin (2010 - 2026) Analysis & Trends

Omeros (OMER) has 14 years of EBT Margin data on file, last reported at 518.61% in Q1 2026.

For the quarter ending Q1 2026, EBT Margin changed N/A year-over-year to 518.61%; the trailing twelve-month figure through Mar 2026 stood at 284.5% (down 59851.0% YoY), and the FY2020 full-year result was 266.06%, down 11657.0% from the prior year.
EBT Margin grew to 518.61% in Q1 2026, from 412.74% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 518.61% in Q1 2026 to a low of 579.19% in Q1 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	17.13%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	41.95%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.05%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	34.77%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Omeros	739.31 Mn	739.31 Mn	9.31 Mn	518.61%

Historic Data

Download Data

Date	Value
Mar 31, 2026	518.61%
Jun 30, 2022	-412.74%
Mar 31, 2022	-579.19%
Dec 31, 2021	131.63%
Sep 30, 2021	-75.67%
Jun 30, 2021	-275.27%
Mar 31, 2021	-243.51%
Dec 31, 2020	-825.31%
Sep 30, 2020	-177.36%
Jun 30, 2020	-507.88%
Mar 31, 2020	-125.67%
Dec 31, 2019	-334.80%
Sep 30, 2019	-55.14%
Jun 30, 2019	-228.96%
Mar 31, 2019	-114.05%
Dec 31, 2018	-65.57%
Sep 30, 2018	-3,687.63%
Jun 30, 2018	-6,579.46%
Mar 31, 2018	-1,921.54%
Dec 31, 2017	-178.19%